Literature DB >> 2226544

Cystic fibrosis, pathophysiological and clinical aspects.

H J Neijens1, M Sinaasappel, R de Groot, J C de Jongste, S E Overbeek.   

Abstract

Cystic fibrosis is a lethal, hereditary, until recently little understood disease, which leads to progressive functional disturbances in various organs, including the lungs, liver and pancreas. Knowledge of the genetic and cellular abnormalities is rapidly progressing, but therapy is still symptomatic and based on insufficiently controlled and short-term studies. At present the therapeutic approach aims to combat respiratory infections by optimal antibiotic therapy, combined with techniques to promote sputum evacuation. Additional measures attempt to optimise both nutritional state and physical condition. Median survival has improved from approximately 1 year to about 25 years during the past 3 decades. This article summarises present information on disease mechanisms and treatment.

Entities:  

Mesh:

Year:  1990        PMID: 2226544     DOI: 10.1007/bf01957271

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  113 in total

1.  LIGHT AND ELECTRON MICROSCOPIC EXAMINATION OF THE SMALL BOWEL OF CHILDREN WITH CYSTIC FIBROSIS.

Authors:  H B FREYE; S M KURTZ; A SPOCK; M P CAPP
Journal:  J Pediatr       Date:  1964-04       Impact factor: 4.406

2.  Pneumothorax in cystic fibrosis: a 26-year experience.

Authors:  M L Spector; R C Stern
Journal:  Ann Thorac Surg       Date:  1989-02       Impact factor: 4.330

3.  Cumulative and acute toxicity of repeated high-dose tobramycin treatment in cystic fibrosis.

Authors:  S S Pedersen; T Jensen; D Osterhammel; P Osterhammel
Journal:  Antimicrob Agents Chemother       Date:  1987-04       Impact factor: 5.191

4.  Intrapleural instillation of quinacrine for recurrent pneumothorax. Use in a patient with cystic fibrosis.

Authors:  J Kattwinkel; L M Taussig; C L McIntosh; P A di Sant'Agnese; R E Wood
Journal:  JAMA       Date:  1973-10-29       Impact factor: 56.272

5.  Face mask physiotherapy in cystic fibrosis.

Authors:  J C Tyrrell; E J Hiller; J Martin
Journal:  Arch Dis Child       Date:  1986-06       Impact factor: 3.791

Review 6.  The cystic fibrosis defect approached from different angles--new perspectives on the gene, the chloride channel, diagnosis and therapy.

Authors:  D J Halley; J Bijman; H R de Jonge; M Sinaasappel; H J Neijens; M F Niermeijer
Journal:  Eur J Pediatr       Date:  1990-07       Impact factor: 3.183

7.  Progression of cystic fibrosis lung disease as a function of serum immunoglobulin G levels: a 5-year longitudinal study.

Authors:  W B Wheeler; M Williams; W J Matthews; H R Colten
Journal:  J Pediatr       Date:  1984-05       Impact factor: 4.406

8.  Imipenem/cilastatin in acute pulmonary exacerbations of cystic fibrosis.

Authors:  L R Krilov; J L Blumer; R C Stern; A I Hartstein; B N Iglewski; D A Goldmann
Journal:  Rev Infect Dis       Date:  1985 Jul-Aug

9.  Effect of taurine supplementation on fat and bile acid absorption in patients with cystic fibrosis.

Authors:  C Colombo; S Arlati; L Curcio; R Maiavacca; M Garatti; M Ronchi; C Corbetta; A Giunta
Journal:  Scand J Gastroenterol Suppl       Date:  1988

10.  Interaction of pseudomonas exoproducts with phagocytic cells.

Authors:  B Weber; M M Nickol; K S Jagger; C B Saelinger
Journal:  Can J Microbiol       Date:  1982-06       Impact factor: 2.419

View more
  2 in total

Review 1.  The cystic fibrosis defect approached from different angles--new perspectives on the gene, the chloride channel, diagnosis and therapy.

Authors:  D J Halley; J Bijman; H R de Jonge; M Sinaasappel; H J Neijens; M F Niermeijer
Journal:  Eur J Pediatr       Date:  1990-07       Impact factor: 3.183

2.  Cystic fibrosis in a 70 year old woman.

Authors:  P van Biezen; S E Overbeek; C Hilvering
Journal:  Thorax       Date:  1992-03       Impact factor: 9.139

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.